OTCMKTS:USRM Bioheart (USRM) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 07/24/2026 10:38 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Bioheart Stock (OTCMKTS:USRM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bioheart alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0001Volume54,804 shsAverage Volume256,025 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Bioheart, Inc. is a clinical-stage regenerative medicine company focused on the development and commercialization of autologous adult stem cell therapies for cardiovascular and soft tissue disorders. The company’s primary objective is to harness a patient’s own stem cells to promote tissue repair and restore function in individuals suffering from chronic heart failure, myocardial ischemia and other degenerative conditions. The core of Bioheart’s technology is the Myocardia cell implantation system, a point-of-care solution that integrates proprietary cell-separation reagents with a catheter-based delivery platform. This system isolates and concentrates mononuclear cells from either bone marrow or peripheral blood and delivers them directly to the targeted tissue, with ongoing research into applications such as ischemic cardiomyopathy, non-healing diabetic ulcers and musculoskeletal repair. Founded in 2003 and incorporated in Delaware, Bioheart is headquartered in Florida and operates primarily in the United States, with collaborations in selected international markets to advance its clinical programs. The company has successfully advanced multiple product candidates through early-stage human studies, aiming to secure regulatory approvals and strategic alliances that will support large-scale manufacturing and commercialization. Bioheart’s management team brings together experts in cell therapy development, medical device regulation and biotechnology commercialization. Leveraging a growing intellectual property portfolio, the company continues to refine its regenerative treatment platforms and pursue partnerships designed to accelerate the adoption of its cell-based therapies in clinical practice.AI Generated. May Contain Errors. Read More Receive USRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioheart and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. USRM Stock News HeadlinesUSRM U.S. Stem Cell, Inc.July 7, 2026 | seekingalpha.comUS Stem Cell Stock Price HistoryDecember 10, 2025 | investing.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.July 25 at 1:00 AM | InvestorPlace (Ad)Kennedy Says ‘Charlatans’ Are No Reason to Block Unproven Stem Cell TreatmentsJune 5, 2025 | nytimes.comThe Allure of Stem Cell TherapyJune 5, 2025 | nytimes.comHow our bones are repaired by skeletal stem cells: Scientist discover four major subtypesJune 4, 2025 | msn.comFirst Stem Cell Nerve Therapy Meant to Reverse Paralysis Enters Clinical TrialMay 28, 2025 | msn.comVascularized stem cell islet organoids offer improved model for diabetes researchMay 23, 2025 | msn.comSee More Headlines USRM Stock Analysis - Frequently Asked Questions How have USRM shares performed this year? Bioheart's stock was trading at $0.0001 on February 2, 2026. Since then, USRM stock has increased by 0.0% and is now trading at $0.0001. How were Bioheart's earnings last quarter? Bioheart Inc. (OTCMKTS:USRM) released its quarterly earnings data on Wednesday, August, 7th. The company reported $0.00 earnings per share for the quarter. The business had revenue of $1.30 million for the quarter. How do I buy shares of Bioheart? Shares of USRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bioheart own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioheart investors own include Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Cannabis Wheaton Income (CBWTF), Meta Platforms (META), Nextech3D.AI (NEXCF) and Orion Energy Systems (OESX). Company Calendar Last Earnings8/07/2019Today7/25/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBusiness Services Current SymbolOTCMKTS:USRM Previous SymbolNASDAQ:BHRT CIK1388319 Webwww.us-stemcell.com Phone(954) 835-1500Fax954-845-9976Employees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.96 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:USRM) was last updated on 7/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioheart Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioheart With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
